Literature DB >> 29564676

The Catalytically Inactive Mutation of the Ubiquitin-Conjugating Enzyme CDC34 Affects its Stability and Cell Proliferation.

Xun Liu1, Yang Zhang1, Zhanhong Hu1, Qian Li1, Lu Yang1, Guoqiang Xu2.   

Abstract

The ubiquitin proteasome system (UPS) plays important roles in the regulation of protein stability, localization, and activity. A myriad of studies have focused on the functions of ubiquitin ligases E3s and deubiquitinating enzymes DUBs due to their specificity in the recognition of downstream substrates. However, the roles of the most ubiquitin-conjugating enzymes E2s are not completely understood except that they transport the activated ubiquitin and form E2-E3 protein complexes. Ubiquitin-conjugating enzyme CDC34 can promote the degradation of downstream targets through the UPS whereas its non-catalytic functions are still elusive. Here, we find that mutation of the catalytically active cysteine to serine (C93S) results in the reduced ubiquitination, increased stability, and attenuated degradation rate of CDC34. Through semi-quantitative proteomics, we identify the CDC34-interacting proteins and discover that the wild-type and mutant proteins have many differentially interacted proteins. Detailed examination finds that some of them are involved in the regulation of gene expression, cell growth, and cell proliferation. Cell proliferation assay reveals that both the wild-type and C93S proteins affect the proliferation of a cancer cell line. Database analyses show that CDC34 mRNA is highly expressed in multiple cancers, which is correlated with the reduced patient survival rate. This work may help to elucidate the enzymatic and non-enzymatic functions of this protein and might provide additional insights for drug discovery targeting E2s.

Entities:  

Keywords:  CDC34; Catalytic site; Cell proliferation; Protein degradation; Proteomics; Ubiquitination

Mesh:

Substances:

Year:  2018        PMID: 29564676     DOI: 10.1007/s10930-018-9766-x

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  46 in total

1.  Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity.

Authors:  F Gharahdaghi; C R Weinberg; D A Meagher; B S Imai; S M Mische
Journal:  Electrophoresis       Date:  1999-03       Impact factor: 3.535

2.  Protein C-terminal enzymatic labeling identifies novel caspase cleavages during the apoptosis of multiple myeloma cells induced by kinase inhibition.

Authors:  Wenwen Duan; Suping Chen; Yang Zhang; Dan Li; Rong Wang; Shi Chen; Junbei Li; Xiaoyan Qiu; Guoqiang Xu
Journal:  Proteomics       Date:  2015-11-30       Impact factor: 3.984

3.  In-gel digestion for mass spectrometric characterization of proteins and proteomes.

Authors:  Andrej Shevchenko; Henrik Tomas; Jan Havlis; Jesper V Olsen; Matthias Mann
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Profiling lysine ubiquitination by selective enrichment of ubiquitin remnant-containing peptides.

Authors:  Guoqiang Xu; Alessia Deglincerti; Jeremy S Paige; Samie R Jaffrey
Journal:  Methods Mol Biol       Date:  2014

5.  USP13 enzyme regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding domains.

Authors:  Marzia Scortegagna; Tony Subtil; Jianfei Qi; Hyungsoo Kim; Wenhui Zhao; Wei Gu; Harriet Kluger; Ze'ev A Ronai
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

6.  Phosphorylation of the human ubiquitin-conjugating enzyme, CDC34, by casein kinase 2.

Authors:  K Block; T G Boyer; P R Yew
Journal:  J Biol Chem       Date:  2001-09-06       Impact factor: 5.157

7.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Vasudeva Mahavisno; Radhika Varambally; Jianjun Yu; Benjamin B Briggs; Terrence R Barrette; Matthew J Anstet; Colleen Kincead-Beal; Prakash Kulkarni; Sooryanaryana Varambally; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

8.  Cdc34 and the F-box protein Met30 are required for degradation of the Cdk-inhibitory kinase Swe1.

Authors:  P Kaiser; R A Sia; E G Bardes; D J Lew; S I Reed
Journal:  Genes Dev       Date:  1998-08-15       Impact factor: 11.361

Review 9.  The MCM complex: its role in DNA replication and implications for cancer therapy.

Authors:  Ming Lei
Journal:  Curr Cancer Drug Targets       Date:  2005-08       Impact factor: 3.428

10.  Inhibitors of the Cdc34 acidic loop: A computational investigation integrating molecular dynamics, virtual screening and docking approaches.

Authors:  Alberto Arrigoni; Luca Bertini; Luca De Gioia; Elena Papaleo
Journal:  FEBS Open Bio       Date:  2014-05-09       Impact factor: 2.693

View more
  2 in total

Review 1.  Beyond repression of Nrf2: An update on Keap1.

Authors:  Aleksandra Kopacz; Damian Kloska; Henry Jay Forman; Alicja Jozkowicz; Anna Grochot-Przeczek
Journal:  Free Radic Biol Med       Date:  2020-03-28       Impact factor: 7.376

Review 2.  The Molecular Basis of Ubiquitin-Conjugating Enzymes (E2s) as a Potential Target for Cancer Therapy.

Authors:  Xiaodi Du; Hongyu Song; Nengxing Shen; Ruiqi Hua; Guangyou Yang
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.